US 11,052,136 B2
Prevention and/or treatment of ischemia or ischemia/reperfusion injury
Lina Badimon Maestro, Barcelona (ES); Judit Cubedo Ràfols, Barcelona (ES); Gemma Vilahur Garcia, Barcelona (ES); and Teresa Padró Capmany, Barcelona (ES)
Assigned to FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU, Barcelona (ES)
Appl. No. 16/84,521
Filed by FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU, Barcelona (ES)
PCT Filed Mar. 14, 2017, PCT No. PCT/EP2017/056027
§ 371(c)(1), (2) Date Sep. 12, 2018,
PCT Pub. No. WO2017/157958, PCT Pub. Date Sep. 21, 2017.
Claims priority of application No. 16382111 (EP), filed on Mar. 14, 2016.
Prior Publication US 2019/0076509 A1, Mar. 14, 2019
Int. Cl. A61K 38/46 (2006.01)
CPC A61K 38/465 (2013.01) [C12Y 301/01002 (2013.01)] 22 Claims
 
1. A pharmaceutical composition comprising the DJ-1-17 polypeptide consisting of SEQ ID NO: 1 or a functionally equivalent variant thereof having at least 97% sequence identity with the DJ-1-17 polypeptide consisting of SEQ ID NO: 1, the GRP75 polypeptide consisting of SEQ ID NO: 3 or a functionally equivalent variant thereof having at least 97% sequence identity with the GRP75 polypeptide consisting of SEQ ID NO: 3, and/or the PRDX6 polypeptide consisting of SEQ ID NO: 4 or a functionally equivalent variant thereof having at least 97% sequence identity with the PRDX6 polypeptide consisting of SEQ ID NO: 4, and a pharmaceutically acceptable excipient.